Bd reports third quarter fiscal 2024 financial results

Strong margin execution drives performance in quarter revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth gaap and adjusted diluted eps of $1.68 and $3.50 grew 23.5% and 18.2%, respectively year-to-date cash from continuing operations grew 60% to $2.7 billion and free cash flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectively the company updated its fiscal 2024 gaap revenue growth guidance to approximately 3.7%, and its organic revenue growth guidance to 5.0% to 5.25% the company increased its fiscal 2024 adjusted diluted eps guidance by 5 cents at the midpoint to $13.05 to $13.15 1 franklin lakes, n.j. , aug. 1, 2024 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its third quarter of fiscal 2024, which ended june 30, 2024.
BDX Ratings Summary
BDX Quant Ranking